Key result
In patients with chronic kidney disease treated with RAAS inhibitors, hyperkalemia occurred in 9.2% of patients, and 55.3% of those experiencing hyperkalemia subsequently discontinued or reduced their RAAS inhibitor therapy.
Why the study?
Hyperkalemia is common in patients treated with RAAS inhibitors and represents the main cause of the gap between guideline recommendations and real-world practice in CKD.
What is the incidence of hyperkalemia and the rate of subsequent medication changes in patients with CKD treated with RAAS inhibitors?
Cohort (n=556)
No
What is the incidence of hyperkalemia and the rate of subsequent medication changes in patients with CKD treated with RAAS inhibitors?
Hyperkalemia is a frequent complication of RAAS inhibitor therapy in CKD patients, often leading to potentially detrimental discontinuation or dose reduction of these guideline-directed therapies.
Hyperkalemia prompts frequent RAAS inhibitor changes in CKD; leaves open whether potassium management can preserve therapy benefits.
Hyperkalemia is common in patients treated with renin–angiotensin–aldosterone system inhibitors (RAASis), and it represents the main cause of the large gap reported between guideline recommendations and real-world practice in chronic kidney disease (CKD). We conducted a CKD-population-based restrospective study to determine the prevalence of patients with CKD treated with RAASis, incidence of hyperkalemia in patients with CKD treated with RAASis, and proportion of patients with RAASi medication change after experiencing incident hyperkalemia. Among 809 patients with CKD analyzed, 556 (68.7%) were treated with RAASis, and RAASi prescription was greater in stages 2–4 of CKD. Hyperkalemia occurred in 9.2% of RAASi-treated patients, and the adjusted rate of hyperkalemia among patients with stage 4–5 CKD was 3-fold higher compared with patients with eGFR > 60 ml/min/1.73 m 2 . RAASi treatment was discontinued in 55.3% of the patients after hyperkalemia event (74.2% discontinued therapy, 3.2% received a reduced dose, and 22.6% reduced the number of RAASi drugs). This study shows that the incidence of hyperkalemia is frequently observed in patients with CKD patients with RAASis, and that rates increase with deteriorating levels of kidney function from stages 1 to 3. RAASi medication change following an episode of hyperkalemia occurred in almost half of the patients after experiencing hyperkalemia.
No takes yet. Share an insight, caveat, or question.
Riccio et al. (2022) conducted a cohort in Chronic Kidney Disease (n=556). RAAS inhibitors was evaluated on Incidence of hyperkalemia. In patients with chronic kidney disease treated with RAAS inhibitors, hyperkalemia occurred in 9.2% of patients, and 55.3% of those experiencing hyperkalemia subsequently discontinued or reduced their RAAS inhibitor therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: